These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 33291033)

  • 1. Variations in consecutive serum neurofilament light levels in healthy controls and multiple sclerosis patients.
    Bridel C; Verberk IMW; Heijst JJA; Killestein J; Teunissen CE
    Mult Scler Relat Disord; 2021 Jan; 47():102666. PubMed ID: 33291033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of elevated sNFL in a real-world setting: Results on 908 patients with different multiple sclerosis types and treatment conditions.
    Bava CI; Valentino P; Malucchi S; Bottero R; Martire S; Sapio AD; Bertolotto A
    Mult Scler Relat Disord; 2024 Aug; 88():105748. PubMed ID: 38959590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum neurofilament light chain levels in healthy individuals: A proposal of cut-off values for use in multiple sclerosis clinical practice.
    Valentino P; Marnetto F; Martire S; Malucchi S; Bava CI; Popovic M; Bertolotto A
    Mult Scler Relat Disord; 2021 Sep; 54():103090. PubMed ID: 34182224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NfL predicts relapse-free progression in a longitudinal multiple sclerosis cohort study.
    Uphaus T; Steffen F; Muthuraman M; Ripfel N; Fleischer V; Groppa S; Ruck T; Meuth SG; Pul R; Kleinschnitz C; Ellwardt E; Loos J; Engel S; Zipp F; Bittner S
    EBioMedicine; 2021 Oct; 72():103590. PubMed ID: 34571362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis.
    Siller N; Kuhle J; Muthuraman M; Barro C; Uphaus T; Groppa S; Kappos L; Zipp F; Bittner S
    Mult Scler; 2019 Apr; 25(5):678-686. PubMed ID: 29542376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: A longitudinal retrospective 5-year study.
    Jakimovski D; Zivadinov R; Ramanthan M; Hagemeier J; Weinstock-Guttman B; Tomic D; Kropshofer H; Fuchs TA; Barro C; Leppert D; Yaldizli Ö; Kuhle J; Benedict RH
    Mult Scler; 2020 Nov; 26(13):1670-1681. PubMed ID: 31610732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline serum neurofilament light chain levels differentiate aggressive from benign forms of relapsing-remitting multiple sclerosis: a 20-year follow-up cohort.
    Arroyo Pereiro P; Muñoz-Vendrell A; León Moreno I; Bau L; Matas E; Romero-Pinel L; Martínez Yélamos A; Martínez Yélamos S; Andrés-Benito P
    J Neurol; 2024 Apr; 271(4):1599-1609. PubMed ID: 38085343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis.
    Disanto G; Barro C; Benkert P; Naegelin Y; Schädelin S; Giardiello A; Zecca C; Blennow K; Zetterberg H; Leppert D; Kappos L; Gobbi C; Kuhle J;
    Ann Neurol; 2017 Jun; 81(6):857-870. PubMed ID: 28512753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early neurofilament light and glial fibrillary acidic protein levels improve predictive models of multiple sclerosis outcomes.
    Bose G; Healy BC; Saxena S; Saleh F; Paul A; Barro C; Lokhande HA; Polgar-Turcsanyi M; Anderson M; Glanz BI; Guttmann CRG; Bakshi R; Weiner HL; Chitnis T
    Mult Scler Relat Disord; 2023 Jun; 74():104695. PubMed ID: 37060852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum neurofilament light is a sensitive biomarker that reflects grey matter volume in Japanese patients with multiple sclerosis.
    Fujimori J; Nakashima I
    J Neurol Sci; 2021 Aug; 427():117528. PubMed ID: 34098375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study.
    Bittner S; Steffen F; Uphaus T; Muthuraman M; Fleischer V; Salmen A; Luessi F; Berthele A; Klotz L; Meuth SG; Bayas A; Paul F; Hartung HP; Linker R; Heesen C; Stangel M; Wildemann B; Then Bergh F; Tackenberg B; Kuempfel T; Weber F; Zettl UK; Ziemann U; Tumani H; Groppa S; Mühlau M; Lukas C; Hemmer B; Wiendl H; Gold R; Zipp F;
    EBioMedicine; 2020 Jun; 56():102807. PubMed ID: 32460167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum neurofilament levels correlate with retinal nerve fiber layer thinning in multiple sclerosis.
    Bsteh G; Berek K; Hegen H; Teuchner B; Buchmann A; Voortman MM; Auer M; Wurth S; Zinganell A; Di Pauli F; Deisenhammer F; Khalil M; Berger T
    Mult Scler; 2020 Nov; 26(13):1682-1690. PubMed ID: 31668116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroaxonal and Glial Markers in Patients of the Same Age With Multiple Sclerosis.
    Loonstra FC; de Ruiter LRJ; Koel-Simmelink MJA; Schoonheim MM; Strijbis EMM; Moraal B; Barkhof F; Uitdehaag BMJ; Teunissen C; Killestein J
    Neurol Neuroimmunol Neuroinflamm; 2023 Mar; 10(2):. PubMed ID: 36543540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of alemtuzumab over sNfL and sGFAP levels in multiple sclerosis.
    Sainz-Amo R; Rodero Romero A; Monreal E; Chico García JL; Fernández Velasco JI; Villarrubia N; Veiga González JL; Sainz de la Maza S; Rodríguez Jorge F; Masjuan J; Costa-Frossard L; Villar LM
    Front Immunol; 2024; 15():1454474. PubMed ID: 39224593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in serum neurofilament light chain levels following narrowband ultraviolet B phototherapy in clinically isolated syndrome.
    Fabis-Pedrini MJ; Kuhle J; Roberts KMA; Trend S; Jones AP; Maceski A; Carroll WM; Lucas RM; Mastaglia FL; Hart PH; Kermode AG
    Brain Behav; 2022 Feb; 12(2):e2494. PubMed ID: 35084124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis.
    Meier S; Willemse EAJ; Schaedelin S; Oechtering J; Lorscheider J; Melie-Garcia L; Cagol A; Barakovic M; Galbusera R; Subramaniam S; Barro C; Abdelhak A; Thebault S; Achtnichts L; Lalive P; Müller S; Pot C; Salmen A; Disanto G; Zecca C; D'Souza M; Orleth A; Khalil M; Buchmann A; Du Pasquier R; Yaldizli Ö; Derfuss T; Berger K; Hermesdorf M; Wiendl H; Piehl F; Battaglini M; Fischer U; Kappos L; Gobbi C; Granziera C; Bridel C; Leppert D; Maleska Maceski A; Benkert P; Kuhle J
    JAMA Neurol; 2023 Mar; 80(3):287-297. PubMed ID: 36745446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of serum neurofilament light with microglial activation in multiple sclerosis.
    Saraste M; Matilainen M; Vuorimaa A; Laaksonen S; Sucksdorff M; Leppert D; Kuhle J; Airas L
    J Neurol Neurosurg Psychiatry; 2023 Sep; 94(9):698-706. PubMed ID: 37130728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. sNFL applicability as additional monitoring tool in natalizumab extended interval dosing regimen for RRMS patients.
    Valentino P; Malucchi S; Martire S; Bava CI; Capobianco MA; Bertolotto A
    Mult Scler Relat Disord; 2022 Nov; 67():104176. PubMed ID: 36126541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal analysis of serum neurofilament light chain: A potential therapeutic monitoring biomarker for multiple sclerosis.
    Hyun JW; Kim Y; Kim G; Kim SH; Kim HJ
    Mult Scler; 2020 May; 26(6):659-667. PubMed ID: 30912689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitamin D supplementation and serum neurofilament light chain in interferon-beta-1b-treated MS patients.
    Hänninen K; Jääskeläinen O; Herukka SK; Soilu-Hänninen M
    Brain Behav; 2020 Sep; 10(9):e01772. PubMed ID: 32705821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.